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Percutaneous coronary intervention (PCI)
using a drug-eluting stent (DES) leads to
less re-stenosis than PCI using a bare
metal stent (BMS), however there is still
controversy whether use of a DES for
severe coronary disease leads to an
acceptable outcome in patients with
diabetes mellitus (DM). In this study 8159
lesions were treated in 6739 patients
(mean age 68.9 years) with coronary
artery disease. Use of a DES significantly
decreased the re-stenosis rate compared
with BMS in both DM (9.6% versus 21.3%)
and non-DM (9.5% versus 17.1%) patients.
The re-stenosis rate was significantly
higher in DM than in non-DM patients in
the BMS group but not in the DES group.
There was no statistically significant
difference in event-free survival after
stenting of patients with left main
coronary artery (LMCA) disease between
the BMS and DES groups. It was
concluded that, compared with BMS, DES
reduced re-stenosis in patients with DM,
however, we advise careful treatment
after using DES for severe coronary
disease, including LMCA lesions, in
patients with DM.
KEY WORDS: PERCUTANEOUS CORONARY INTERVENTION; DRUG-ELUTING STENT; BARE METAL STENT;
CORONARY ARTERY DISEASE; LEFT MAIN CORONARY ARTERY DISEASE; DIABETES MELLITUS; MAJOR ADVERSE
CARDIOVASCULAR EVENTS; CLINICAL OUTCOME
Part of this work was presented at the 74th Annual
Scientific Meeting of the Japanese Circulation Society, 5 –
7 March 2010, Kyoto, Japan.
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Introduction
Introduced about a decade after coronary
artery bypass grafting, percutaneous
coronary intervention (PCI) has come to be
preferred, because it is less invasive, and it is
now widely used to treat coronary artery
disease.1,2 Technological improvements,
especially the development of coronary
stents, have made it possible to treat
complex lesions.3 – 5 However, in previous
randomized trials coronary artery bypass
grafting was superior to PCI for patients with
diabetes or multivessel coronary artery
disease when using plain balloon
angioplasty or a bare metal stent (BMS).6,7
The differences in outcome between
coronary artery bypass grafting and PCI
were mainly associated with re-stenosis of
the treated lesions and target lesion
revascularization (TLR).
The recent advent of drug-eluting stents
(DES) has dramatically reduced the rate of
re-stenosis after PCI, and DES are
particularly superior to BMS in PCI for small
vessels, whether or not the coronary disease
is associated with diabetes mellitus (DM).
Several trials, however, have demonstrated
that DES did not reduce subsequent rates of
major adverse clinical events or mortality,
although they did reduce the rate of target
lesion revascularization compared with the
use of a BMS.8,9 The objective of the present
study was to evaluate the clinical outcomes
of PCI with a stent in the presence and
absence of DM in Japanese patients with
coronary artery disease.
Patients and methods
PATIENTS, SUCCESS CRITERIA AND
TREATMENTS
Consecutive patients who underwent PCI for
coronary artery disease at Kanazawa
University Hospital and affiliate hospitals
(see Appendix for a list of affiliate hospitals)
between January 2006 and December 2008
were eligible for enrolment into the study.
The indications for PCI included stable
angina pectoris, unstable angina and acute
myocardial infarction. Patients who
underwent PCI but were treated without
stenting, using only balloon dilatation,
thrombectomy or directional coronary
atherectomy, were excluded.
All procedural decisions, including device
selection and adjunctive pharmacotherapy,
were made at the discretion of the individual
PCI operator. Intravascular ultrasonography
was used at the operator’s discretion.
Procedural (angiographic) success was
defined as residual stenosis of < 25%. The
definition of clinical success included
angiographic success and the in-hospital
absence of acute myocardial infarction,
congestive heart failure and cardiac death.
Procedural and clinical success were
evaluated at the time the patient was
discharged. 
All patients who underwent PCI with a
stent received dual antiplatelet therapy
comprising aspirin (100 mg/day) and
clopidogrel (75 mg/day) or ticlopidine
(200 mg/day), and continued this therapy
for an appropriate period.
This study was certified by the Ethics
Committee of Kanazawa University.
CLINICAL FOLLOW-UP
All patients were evaluated clinically during
a follow-up visit to the outpatient clinic and
were recommended to receive follow-up
coronary angiography at least 6 months
after the PCI procedure. Angiographic results
and clinical symptoms were used to evaluate
the clinical outcome. Binary re-stenosis was
defined as ≥ 50% stenosis at the target lesion. 
The occurrence of major adverse cardiac
events (MACE), defined as sudden cardiac
death, acute coronary syndrome-related
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target lesions and TLR, was recorded.
Coronary risk factors, comprising DM
(fasting blood glucose > 126 mg/dl or
glycated haemoglobin > 6.5%), hypertension
(blood pressure > 130/85 mmHg), hyper -
cholesterol aemia (total cholesterol
> 220 mg/dl) and smoking, were also
checked and evaluated for association with
re-stenosis.
STATISTICAL ANALYSES
Continuous variables were expressed as
mean ± SD and were compared using
Student’s t-test and analysis of variance.
Categorical data were compared using the χ2
test or Fisher’s exact test. MACE-free survival
distributions were calculated by Kaplan–
Meier analysis and differences were assessed
using the log-rank test. A P-value < 0.05 was
considered statistically significant. All data
analyses were performed using StatView® J
5.0 software (SAS Institute, Cary, NC, USA).
Results
A total of 7660 consecutive patients (5745
men) with 9392 lesions underwent PCI for
coronary artery disease at Kanazawa
University Hospital and affiliate hospitals
between January 2006 and December 2008
and were eligible for enrolment into this
study. Angiography was carried out in 5570
(72.7%) of these patients. Of the 9392 total
number of lesions, 1233 were treated without
stenting (959 using only balloon dilatation
and 274 with thrombectomy or directional
coronary atherectomy) so were excluded
from the analysis. The remaining 8159
lesions in 6739 patients (mean ± SD age 68.9
± 10.5 years; 5103 men) were evaluated and
stenting was successful in 8129 (99.6%)
lesions from 6709 (99.6%) patients. Because
this was a multicentre study, with data
obtained from many hospitals (see
Appendix), it was not possible to obtain data
on all variables for all patients.
TABLE 1:
Baseline clinical and angiographic characteristics in patients treated with a bare metal
stent (BMS) or drug-eluting stent (DES) for coronary artery disease
Statistical 
Characteristic BMS DES significance
No. of patients 2934 3805 NS
No. of lesions treated by PCI 3536 4623 NS
Acute coronary syndrome, No. (%) of 1702 (48.1) 719 (15.6) P < 0.0001
total lesions
Age, years, mean ± SD 68.8 ± 11.2 69.0 ± 10.0 NS
Male, n (%) 2230 (76.0) 2873 (75.5) NS
Coronary risk factors, n (%)
Diabetes mellitus 1171 (39.9) 1899 (49.9) P < 0.0001
Hypertension 1810 (61.7) 2473 (65.0) NS
Hypercholesterolaemia 1338 (45.6) 1750 (46.0) NS
Current smoker 1229 (41.9) 1564 (41.1) NS
Lesion characteristics, n (%)
Single vessel 1623 (55.3) 1925 (50.6) NS
Two vessels 760 (25.9) 1176 (30.9) NS
Three vessels 428 (14.6) 590 (15.5) NS
LMCA 123 (4.2) 114 (3.0) NS
Percentages calculated on the number of patients unless stated otherwise.
PCI, percutaneous coronary intervention; LMCA, left main coronary artery; NS, not statistically significant, P > 0.05.
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BASELINE CHARACTERISTICS
Baseline clinical and angiographic
characteristics of the patients are shown in
Table 1 and were similar in the BMS and DES
groups with the exceptions of the number of
lesions in patients with acute coronary
syndrome (ACS) and the numbers of patients
with DM as a coronary risk factor. A total of
2421 lesions were associated with ACS: 1702
(48.1%) and 719 (15.6%) BMS- and DES-
treated lesions, respectively (P < 0.0001). DM
was associated with 3070 patients: 1171
(39.9%) BMS-treated patients and 1899
(49.9%) DES-treated patients (P < 0.0001).
IN-HOSPITAL OUTCOMES
Angiographic success was obtained in 6618
(98.2%) and clinical success in 6476 (96.1%)
patients. Within 30 days after the procedure,
stent-related MACE were observed in 74 (1.1%)
patients, including 49 (0.7%) deaths and 25
(0.4%) cases of ACS, comprising 21 (0.3%)
cases of myocardial infarction and four
(0.05%) cases of unstable angina associated
with angiographically confirmed subacute
stent thrombosis (Table 2). The frequency of
MACE up to 30 days after the procedure was
significantly higher in the BMS group than in
the DES group (P < 0.0001). 
LONG-TERM OUTCOMES
Re-stenosis and TLR
All cases of successful stenting (8129 lesions
from 6709 patients) were clinically followed
up for a period of 3 years and 5975 lesions
(73.5%) underwent follow-up coronary
angiography after the initial procedure
(mean ± SD follow-up interval 7.3 ± 4.9
months). The number of lesions for which re-
stenosis was carried out was significantly
lower in the DES group than in the BMS
group: 445 of 4623 (9.6%) lesions versus 661
of 3536 (18.7%) lesions (relative risk 1.94 for
the BMS group versus the DES group;
P < 0.01; Fig. 1). Similarly, the rate of TLR
was also significantly lower in the DES group
than in the BMS group: 327 of 4623 (7.1%)
lesions versus 472 of 3536 (13.6%) lesions
(relative risk 1.46 for the BMS group versus
the DES group; P < 0.01; Fig. 1). The long-
term cumulative frequency of MACE in
patients with ACS was similar in the BMS and
DES groups: 83/1702 (4.9%) and 26/719
(3.6%) patients, respectively.
BMS DES Statistical 
Variable (n = 2934) (n = 3805) significance
No. of lesions treated by PCI 3536 4623
In-hospital MACEa P < 0.0001
Death, n (%) 40 (1.4) 9 (0.2) P < 0.0001
Acute coronary syndrome 12 (0.4) 13 (0.3) NS
Long-term cumulative MACEb NS
Death, n (%) 39 (1.3) 24 (0.6) NS
Acute coronary syndrome, n (%) 20 (0.7) 26 (0.7) NS
TLR (% of total lesions) 472 (13.3) 327 (7.1) NS
aIn-hospital data refer to an interval of up to 30 days after the PCI procedure.
bLong-term data refer to the interval from 1 month to 1 year after percutaneous coronary intervention (PCI).
TLR, target lesion revascularization; NS, not statistically significant, P > 0.05.
TABLE 2:
In-hospital and long-term cumulative major adverse cardiovascular events (MACE) in
patients treated with a bare metal stent (BMS) or drug-eluting stent (DES) for coronary
artery disease
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Subgroup analysis of re-stenosis 
The overall in-stent re-stenosis rate was
significantly (P < 0.05) greater in patients
with DM (553/3070 patients; 18.0%) than in
patients without DM (587/3669 patients;
16.0%). There was, however, no statistically
significant effect of DM on the re-stenosis
rate in the DES group (182/1899 patients
[9.6%] with DM compared with 181/1906
patients without DM [9.5%]) whereas DM
did have a statistically significant effect in
the BMS group (249/1171 patients [21.3%]
with DM compared with 301/1763 patients
without DM [17.1%]; P < 0.01) (Fig. 2). There
was no significant effect of other coronary
risk factors with regard to the occurrence of
re-stenosis.
Event-free survival analysis
Evaluation of event-free survival after
stenting was examined in the BMS and DES
groups by Kaplan–Meier analysis (Fig. 3). In
one- and two-vessel disease, event-free
survival decreased until about 200 and 300
days after stenting in patients treated with
BMS and DES, respectively, and was
significantly higher in the DES group than in
the BMS group (P < 0.001). In three-vessel
disease, event-free survival was also higher
in the DES group than in the BMS group
(P < 0.001) and the pattern of the Kaplan–
Meier survival curves was similar to that of
one- and two-vessel disease. In terms of
patients fitted with a DES, event-free survival
did not differ significantly between patients
with one- or two-vessel disease and those
with three-vessel disease, however, among
patients treated with a BMS the long-term
outcome of three-vessel disease was
significantly worse than that of one- or two-
vessel disease (P < 0.001). Event-free survival
also decreased until 200 and 300 days after
stenting of patients with LMCA disease in the
BMS and DES groups, respectively, but the
eventual survival rate did not differ
significantly between these two groups.
FIGURE 1: Rates of re-stenosis and target lesion revascularization (TLR) in patients
treated with a bare metal stent (BMS) or a drug-eluting stent (DES) for coronary artery
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Among patients with LMCA disease, event-
free survival was significantly higher in
those with non-bifurcation lesions (76/82
patients; 92.7%) than in those with
bifurcation lesions (124/155 patients; 80.0%)
(P = 0.0433). The outcome of LMCA lesions
treated with a BMS or DES was worse than
that of non-LMCA lesions and survival with
FIGURE 2: Re-stenosis rate 3 years after treatment with a bare metal stent (BMS) or a
drug-eluting stent (DES) for coronary artery disease in patients with and without



























FIGURE 3: Unadjusted event-free Kaplan–Meier survival curves for patients with one-
or two-vessel coronary artery disease (1&2VD), three-vessel disease (3VD) and left
main coronary artery (LMCA) disease treated with a bare metal stent (BMS) or drug-
eluting stent (DES) (NS, not statistically significant, P > 0.05)
3VD1&2VD LMCA
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a DES was superior to that with a BMS in
patients with non-LMCA lesions (data not
shown).
Discussion
The present study revealed that PCI in a real-
world population was safe and feasible, with
an angiographic procedural success rate of
98.2%, and the BMS and DES treatments
were associated with low rates of MACE.
Although the in-hospital MACE rate in the
BMS group was significantly (P < 0.0001)
higher than that in the DES group, this was
considered to be because of the significantly
higher incidence of patients with ACS who
were treated with a BMS. There was no
significant difference in MACE between the
two groups when comparison was restricted
only to patients showing ACS after stenting.
Implantation of a DES could reduce the
risk of TLR by 40%, although it might also
carry a minor risk of stent thrombosis and
myocardial infarction within 2.7 years
compared with BMS implantation.10,11 In the
present study, the relative risk of TLR
following BMS implantation was 1.46 that of
DES, however there were no differences
between DES and BMS in the long-term risks
of MACE (death, myocardial infarction or
unstable angina associated with stent
thrombosis). This may be explained by the
fact that intravascular ultrasound and
continuous dual antiplatelet therapy were
frequently used.
It has been shown that DM is one of the
most substantial risk factors for re-stenosis
after stent implantation, with odds ratios of
1.9 – 2.5.12 In the present study, using a DES
led to a decrease in the rate of TLR compared
with using a BMS, particularly in patients
with DM. This result was consistent with a
previous study in which TLR rates associated
with a DES, during 4 years of follow-up, were
9.7% and 8.7% for patients with and without
DM, respectively, and rates associated with a
BMS were 22.4% and 16.4%, respectively.13
Re-stenotic intimal hyperplasia in patients
with DM may differ from that in patients
without DM in terms of cellular aspects.14,15
For example, diabetic vascular smooth
muscle cells have been shown to exhibit
increased rates of proliferation, leading to
luminal narrowing.14 A polymer coating,
that releases anti-inflammatory and
antiproliferative agents, is used in DES15 and
this may effectively prevent intimal
proliferation in patients with or without
DM.16 We have reported previously that the
use of a DES could suppress out-stent plaque
progression, which was closely related to the
progression of intimal hyperplasia17 and this
effect may be particularly relevant in the
presence of DM.
The late outcome of one- and two-vessel
disease, three-vessel disease and LMCA
disease after DES and BMS implantation was
evaluated in the present study. Event-free
survival did not differ significantly between
patients with one- or two-vessel disease and
those with three-vessel coronary disease
treated with a DES however, among patients
treated with a BMS, the long-term outcome
of three-vessel disease was worse than that of
one- or two-vessel disease, probably because
multivessel disease is often associated with
multiple coronary risk factors.18
The outcome of LMCA lesions treated with
a BMS or DES was worse than that of non-
LMCA lesions. Although the eventual
survival rate was not significantly different
between the BMS and DES groups in LMCA
disease, survival in patients fitted with a DES
was superior to those with BMS in patients
with non-LMCA lesions. Differences were
particularly notable in bifurcation lesions. It
is commonly thought that stenting for
bifurcation lesions is associated with a high
re-stenosis rate and this might have a
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